Screener
ImmunityBio, Inc. IBRX Debt Issuance Proceeds
Debt Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromShortTermDebt.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net share settlement for RSUs vesting | (6,994) | (1,202) |
| Proceeds from exercises of stock options | 971 | 220 |
| Principal payments on premium financing | (868) | — |
| Proceeds from borrowings | 61 | — |
| Principal payments of finance leases | (13) | — |
| Net cash provided by (used in) financing activities | 223,926 | (982) |
| Effect of exchange rate changes on cash and cash equivalents, and restricted cash | 122 | (10) |
| Net change in cash and cash equivalents, and restricted cash | 117,039 | (82,768) |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s debt issuance proceeds?
- ImmunityBio, Inc. (IBRX) reported debt issuance proceeds of $61K in Q1 2026.
- What does debt issuance proceeds mean?
- Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.
Ask your AI about ImmunityBio, Inc.'s debt issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude